1. Home
  2. EAD vs ARMP Comparison

EAD vs ARMP Comparison

Compare EAD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Income Opportunities Fund

EAD

Allspring Income Opportunities Fund

N/A

Current Price

$6.51

Market Cap

391.8M

Sector

Finance

ML Signal

N/A

ARMP

Armata Pharmaceuticals Inc.

N/A

Current Price

$8.99

Market Cap

383.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EAD
ARMP
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
391.8M
383.7M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
EAD
ARMP
Price
$6.51
$8.99
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
159.5K
40.8K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
8.91%
N/A
EPS Growth
N/A
53.40
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.89
$0.90
52 Week High
$7.18
$13.75

Technical Indicators

Market Signals
Indicator
EAD
ARMP
Relative Strength Index (RSI) 31.94 46.46
Support Level N/A $5.14
Resistance Level $6.91 $12.11
Average True Range (ATR) 0.08 0.93
MACD -0.02 -0.41
Stochastic Oscillator 14.93 34.13

Price Performance

Historical Comparison
EAD
ARMP

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: